NASDAQ : AIDX
20/20 Biolabs, Inc. — Key statistics
Healthcare · Medical Devices · United States
Last price 0.213 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.72M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.72M |
| Enterprise Value | -1.25M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 15, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 12.77M |
| Shares Outstanding | 12.77M |
| Shares Change (YoY) | +47.91% |
| Shares Change (QoQ) | +40.92% |
| Owned by Insiders (%) | 13.24% |
| Owned by Institutions (%) | 6.49% |
| Float | 10.84M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.33 |
| Forward PS | 1.39 |
| PB Ratio | 1.61 |
| P/TBV Ratio | 2.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.99 |
| Quick Ratio | 1.90 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.34 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -331.22% |
| Return on Assets (ROA) | -62.37% |
| Return on Invested Capital (ROIC) | -112.07% |
| Return on Capital Employed (ROCE) | -123.20% |
| Weighted Average Cost of Capital (WACC) | 18.23% |
| Revenue Per Employee | $145,729 |
| Profits Per Employee | -$508,216 |
| Employee Count | 14 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 16.18 |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.43 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.42 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 23.52 |
| Average Volume (20 Days) | 155,556 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 11,270 |
| Short Previous Month | 45,167 |
| Short % of Shares Out | 0.09% |
| Short % of Float | 0.10% |
| Short Ratio (days to cover) | 0.12 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 2.04M |
| Gross Profit | 643,094 |
| Operating Income | -4.40M |
| Pretax Income | -5.81M |
| Net Income | -7.12M |
| EBITDA | -4.32M |
| EBIT | -4.40M |
| Loss Per Share | -$1.00 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 4.55M |
| Total Debt | 572,448 |
| Net Cash | 3.97M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | 3.16M |
| Book Value Per Share | 0.13 |
| Working Capital | 2.52M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -2.79M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 78,938 |
| Net Borrowing | 1.17M |
| Free Cash Flow | -2.79M |
| FCF Per Share | -$0.22 |
Margins
| Measure | Value |
|---|
| Gross Margin | 31.52% |
| Operating Margin | -215.69% |
| Pretax Margin | -285.00% |
| Profit Margin | -285.00% |
| EBITDA Margin | -211.83% |
| EBIT Margin | -215.69% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -47.91% |
| Shareholder Yield | -47.91% |
| Earnings Yield | -469.33% |
| FCF Yield | -102.63% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 63.20% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -5.34 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |